

NANOBIOTIX

Société anonyme à directoire et conseil de surveillance au capital de 1 422 805,53 euros
Siège social : 60 rue de Wattignies, 75012 Paris
447 521 600 RCS Paris

INFORMATION REGARDING THE APPLICANT TO THE OFFICE OF SUPERVISORY BOARD MEMBER

GENERAL MEETING OF MAY 19 2025

1. **NAME AND FIRST NAME: SPILLNER ENNO**
2. **AGE: 55 YEARS**
3. **NATIONALITY: GERMAN**
4. **PROFESSIONAL REFERENCES, PROFESSIONAL ACTIVITIES DURING THE LAST FIVE YEARS, CURRENT OR PREVIOUSLY EXERCISED OFFICES IN OTHER COMPANIES**

Mr. Enno Spillner has served as a Supervisory Board member and chairman of the audit committee since 2014. He has 25 years of experience in the life science industry and currently serves as Chief Financial Officer and Member of the Executive Board at Formycon AG. From July 2016 to March 2023, he served as Chief Financial Officer and Member of the Management Board at German biotech company Evotec SE. From March 2013 until June 2016, he served as Chairman of the Management Board, Chief Executive Officer and Chief Financial Officer of 4SC AG. From September 2005 to March 2013 he acted as Chief Financial Officer of 4SC AG. Enno Spillner started his life science industry career as Head of Finance and Managing Partner of the Munich-based biotech venture fund, BioM AG. He was also Managing Director of two portfolio companies, ACTIPAC Biosystems GmbH and Munich innovative Biomaterials GmbH. Currently he also supports Fox Corporate Finance in his role as Member of the Life Science Advisory Board. Prior to moving into the life science field, he was engaged in the media and marketing industry. Enno Spillner earned his Dipl.-Kaufmann degree (Masters in Business) at the University of Bamberg, Germany.

Current exercised offices in other companies:

Chief Financial Officer and Member of the Executive Board	Formycon AG **
---	----------------

** *listed company*

Previously exercised positions or offices expired in the last five years in other companies:

Member of the board of directors and CFO	EVOTEC**
Member of the supervisory board	Leon Nanodrugs

** *listed company*

5. **FUNCTIONS CURRENTLY HELD IN THE COMPANY**

Member of the supervisory board
Chairman of the audit committee

6. **NUMBER OF SHARES OF THE COMPANY HELD BY THE APPLICANT: - NONE**

NANOBIOTIX

Société anonyme à directoire et conseil de surveillance au capital de 1 422 805,53 euros
Siège social : 60 rue de Wattignies, 75012 Paris
447 521 600 RCS Paris

INFORMATION REGARDING THE APPLICANT TO THE OFFICE OF SUPERVISORY BOARD MEMBER

GENERAL MEETING OF MAY 19 2025

- 1. NAME AND FIRST NAME: A. LIU MARGARET**
- 2. AGE: 68 YEARS**
- 3. NATIONALITY: AMERICAN**
- 4. PROFESSIONAL REFERENCES, PROFESSIONAL ACTIVITIES DURING THE LAST FIVE YEARS, CURRENT OR PREVIOUSLY EXERCISED OFFICES IN OTHER COMPANIES**

Dr. Margaret Liu is a world-renowned expert in the fields of gene therapy, vaccines and immunotherapy, Margaret currently serves as Chief Executive Officer (“CEO”) of PAX Therapeutics, as an Adjunct Full Professor at the University of California, San Francisco, and as Hedersdoktor with scientific affiliation in the Department of Medicine at the Karolinska Institutet. Dr. Liu pioneered DNA vaccines and bispecific antibodies and has received a number of international awards. Dr. Liu widely consults for companies and scientific governmental and non-governmental organizations such as the World Health Organization (WHO) through her activities as an individual and as Principal of ProTherImmune, and previously held positions of increasing responsibility at Merck & Co. and Chiron Corporation. She is currently a board member of Ipsen, where she chairs the Ethics and Governance Committee and is a member of the Innovation and Development Committee, and is a member of the board and President Emerita, of the International Society for Vaccines. She also serves on the board of MacroGenics and is a member the Science and Technology Committee. Previously she served on the boards of Transgène, Sangamo Biosciences, Adjuvance Technologies and the United Nations Development Programme-established International Vaccine Institute and was Senior Advisor in Vaccinology at the Bill & Melinda Gates Foundation. Dr. Liu earned an M.D. from Harvard Medical School and completed an internship and residency in Internal Medicine followed by an Endocrinology Fellowship at Massachusetts General Hospital. She also served on the faculty of Harvard Medical School and was a Visiting Scientist at the Massachusetts Institute of Technology. She obtained a B.A. in Chemistry summa cum laude from Colorado College.

Current exercised offices in other companies:

CEO Member of the board of director Member of the board of director Consultant, Santé, Vaccins et Immunothérapie Member of the board of director et Président Emeritus Member of the scientific advisory committee CEO Member of the scientific advisory committee Member of the scientific advisory committee	PAX Therapeutics Ipsen MacroGenics ProTherImmune LLC International Society for Vaccines Jenner Institute, University of Oxford PAX Therapeutics ViroThera Ltd Blue Lake Biotechnology
---	--

Previously exercised positions or offices expired in the last five years in other companies:

Member of the board of director Member of the scientific advisory committee	Adjuvance Technologies Simprin
---	-----------------------------------

5. FUNCTIONS CURRENTLY HELD IN THE COMPANY

Observer

6. NUMBER OF SHARES OF THE COMPANY HELD BY THE APPLICANT – NONE

NANOBIOTIX

Société anonyme à directoire et conseil de surveillance au capital de 1 422 805,53 euros
Siège social : 60 rue de Wattignies, 75012 Paris
447 521 600 RCS Paris

INFORMATION REGARDING THE APPLICANT TO THE OFFICE OF SUPERVISORY BOARD MEMBER

GENERAL MEETING OF MAY 19 2025

- 1. NAME AND FIRST NAME: NASCHITZ ANAT**
- 2. AGE: 57 YEARS**
- 3. NATIONALITY: ISRAËL/ BRITSH**
- 4. PROFESSIONAL REFERENCES, PROFESSIONAL ACTIVITIES DURING THE LAST FIVE YEARS, CURRENT OR PREVIOUSLY EXERCISED OFFICES IN OTHER COMPANIES**

Ms. Anat Naschitz is a life science investor and entrepreneur, with over three decades of experience across biotech, pharmaceuticals, computational R&D, digital health and medical devices, in multiple therapy areas and stages. Throughout her career Ms. Naschitz has founded companies and nurtured them through success with public and private board involvement and investment. Currently, she is building 9vc, a novel lifescience fund. Ms. Naschitz co-founded and co-led OrbiMed Israel as part of the ± \$17bn global healthcare investment firm and was previously with ± €65bn private equity firm Apax where she invested in healthcare companies. Companies Anat has nurtured and on whose boards she has served include 89bio (Nasdaq: ETNB), currently running two cardiometabolic Phase 3 trials, where she led the creation of the company as a pharma spinout and was instrumental in driving a public offering 18 months later, subsequently continuing to serve on the board and several committees; Azura Ophthalmics, in Phase 3 with a drug for Meibomian Gland Disorder which is the root cause behind most dry eye disease; ForSight Vision 6, running a pivotal trial with a truly Accommodating Intraocular Lens under a strategic alliance; TytoCare, a growth-stage company commercializing the Home Smart Clinic; and MDClone, commercializing a synthetic data and analytics platform. Earlier in her career, Ms. Naschitz was an Associate Partner with McKinsey in London, where she advised the senior management of leading pharmaceutical companies on strategy, acquisitions and spinouts. Sobi (STE: SOBI.ST) ultimately resulted from one such spinout. Ms. Naschitz earned her MBA at INSEAD and her LLB at Tel Aviv University.

Current exercised offices in other companies:

Member of the board of director Member of the board of director	PolarisQB ProFuse
--	----------------------

Previously exercised positions or offices expired in the last five years in other companies: none

5. FUNCTIONS CURRENTLY HELD IN THE COMPANY

Observer

6. NUMBER OF SHARES OF THE COMPANY HELD BY THE APPLICANT - NONE